drugset / Trial / NCT05618314

Study of AT-527 in Subjects With Normal and Impaired Renal Function

NCT05618314

Phase 1 Completed 36 enrolled Atea Pharmaceuticals, Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Study of AT-527 in Subjects with Normal and Impaired Renal Function

Timeline

Start
2022-10-17
Primary completion
2024-06-15
Completion
2024-06-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Bemnifosbuvir Other / unclassified
Subject Probenecid Small molecule